Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Zika Virus Purified Inactivated Vaccine (ZPIV) Accelerated Vaccination Schedule Study (Z001)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02937233
Recruitment Status : Completed
First Posted : October 18, 2016
Last Update Posted : August 23, 2018
Sponsor:
Collaborators:
Walter Reed Army Institute of Research (WRAIR)
National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by (Responsible Party):
Kathryn Stephenson, Beth Israel Deaconess Medical Center

Tracking Information
First Submitted Date  ICMJE October 12, 2016
First Posted Date  ICMJE October 18, 2016
Last Update Posted Date August 23, 2018
Actual Study Start Date  ICMJE December 8, 2016
Actual Primary Completion Date June 4, 2018   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: October 17, 2016)
  • Incidence, intensity, and relationship to vaccination of solicited local and systemic adverse events [ Time Frame: 7 days following each vaccination ]
  • Incidence, intensity, and relationship to vaccination of unsolicited local and systemic adverse events [ Time Frame: 28 days following each vaccination ]
  • Incidence, intensity, and relationship to vaccination of serious local and systemic adverse events [ Time Frame: 365 days following each vaccination ]
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: October 17, 2016)
  • ZIKV microneutralization Log10 MN50 titers [ Time Frame: 28 days following last vaccination, and at 6 months ]
  • Zika Env-specific Log10 endpoint ELISA titers [ Time Frame: 28 days following last vaccination, and at 6 months ]
  • Zika Plaque reduction neutralization test titer [ Time Frame: 28 days following last vaccination, and at 6 months ]
  • IFN-γ ELISPOT responses to prM, Env, Cap, and NS1 peptides [ Time Frame: 28 days following last vaccination, and at 6 months ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Zika Virus Purified Inactivated Vaccine (ZPIV) Accelerated Vaccination Schedule Study
Official Title  ICMJE A Phase 1, Randomized, Double-Blind Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of an Accelerated Vaccination Schedule With a Zika Virus Purified Inactivated Vaccine Plus Alum Adjuvant in Healthy Adults
Brief Summary This is a phase 1 trial of one or more administrations of Zika Virus Purified Inactivated Vaccine (ZPIV). The trial will be conducted under a placebo controlled, double-blind, randomized allocation of study product. There are four groups in the study. Each group is testing a different vaccine schedule.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Condition  ICMJE Zika
Intervention  ICMJE
  • Biological: Zika Virus Purified Inactivated Vaccine
  • Other: Placebo
Study Arms  ICMJE
  • Experimental: 4 Week Schedule
    Zika Purified Inactivated Vaccine 5 mcg (or placebo) IM at Week 0 and Week 4
    Interventions:
    • Biological: Zika Virus Purified Inactivated Vaccine
    • Other: Placebo
  • Experimental: 2 Week Schedule
    Zika Purified Inactivated Vaccine 5 mcg (or placebo) IM at Week 0 and Week 2
    Interventions:
    • Biological: Zika Virus Purified Inactivated Vaccine
    • Other: Placebo
  • Experimental: Single Vaccination Schedule
    Zika Purified Inactivated Vaccine 5 mcg (or placebo) IM at Week 0 only
    Interventions:
    • Biological: Zika Virus Purified Inactivated Vaccine
    • Other: Placebo
Publications * Modjarrad K, Lin L, George SL, Stephenson KE, Eckels KH, De La Barrera RA, Jarman RG, Sondergaard E, Tennant J, Ansel JL, Mills K, Koren M, Robb ML, Barrett J, Thompson J, Kosel AE, Dawson P, Hale A, Tan CS, Walsh SR, Meyer KE, Brien J, Crowell TA, Blazevic A, Mosby K, Larocca RA, Abbink P, Boyd M, Bricault CA, Seaman MS, Basil A, Walsh M, Tonwe V, Hoft DF, Thomas SJ, Barouch DH, Michael NL. Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials. Lancet. 2018 Feb 10;391(10120):563-571. doi: 10.1016/S0140-6736(17)33106-9. Epub 2017 Dec 5. Erratum in: Lancet. 2020 Jun 20;395(10241):1906.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: September 27, 2017)
36
Original Estimated Enrollment  ICMJE
 (submitted: October 17, 2016)
48
Actual Study Completion Date  ICMJE June 4, 2018
Actual Primary Completion Date June 4, 2018   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Age 18-50 years old.
  2. Ability and willingness to provide informed consent.
  3. Assessment of understanding: completion of a questionnaire prior to first screening procedure; verbally demonstrate understanding of all questionnaire items answered incorrectly.
  4. Available for the duration of the trial.
  5. Good general health as shown by medical history, physical exam, and screening laboratory tests.
  6. The following laboratory parameters:

    • Hematology

      • Hemoglobin ≥10.5 g/dL for women; ≥11 g/dL for men
      • Absolute Neutrophil Count (ANC): ≥1000/mm3
      • Platelets: 125,000 to 550,000/mm3
    • Chemistry

      • Creatinine: <1.1 x upper limit of normal (ULN)
      • AST: <1.25 x ULN
      • ALT: <1.25 x ULN
    • Normal urinalysis

      • Negative urine glucose.
      • Negative or trace urine protein.
      • Negative or trace urine hemoglobin (if trace hemoglobin is present on dipstick, a microscopic urinalysis within institutional range).
  7. All female participants must be willing to undergo serum or urine beta human chorionic gonadotropin pregnancy tests at time points indicated in the Schedule of Procedures and must test negative prior to vaccination.
  8. All sexually active males (unless anatomically sterile) must be willing to use an effective method of contraception (such as consistent condom use) from the day of first vaccination until Week 12.
  9. If a woman of child-bearing potential, committed to use an effective method of contraception when sexually active with men until Week 12, including:

    • Condoms (male or female) with or without spermicide.
    • Diaphragm or cervical cap with spermicide.
    • Intrauterine device.
    • Hormonal contraception.
    • Successful vasectomy in the male partner (considered successful if a woman reports that a male partner has [1] documentation of azoospermia by microscopy, or [2] a vasectomy more than 2 years ago with no resultant pregnancy despite sexual activity post-vasectomy).
    • Not be of reproductive potential, such as having undergone hysterectomy, bilateral oophorectomy, or tubal ligation.

Exclusion Criteria:

  1. History of known flavivirus infection or previous receipt of flavivirus vaccine.
  2. Positive serology for HIV-1, Hepatitis B surface antigen, or anti-hepatitis C virus antibodies prior to enrollment.
  3. Planned travel to areas with active Zika virus transmission during the study period.
  4. Recent (within 3 weeks) travel to an area with active Zika virus transmission.
  5. Current or planned participation in another clinical trial of an experimental agent during the study period.
  6. Pregnant or lactating.
  7. Any condition, including any clinically significant acute or chronic medical condition, for which, in the opinion of the investigator, participation would not be in the best interest of the subject (eg, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.
  8. Use of anticancer, antituberculosis or other medications considered significant by the investigator within the previous 6 months.
  9. Receipt of live-attenuated vaccine within the previous 60 days or planned receipt within 60 days after vaccination with Investigational Product (within 14 days for live attenuated influenza vaccine [LAIV]); or receipt of other vaccine (e.g., influenza, pneumococcal), allergy treatment with antigen injections or tuberculin skin test within the previous 14 days or planned receipt within 14 days after vaccination with Investigational Product
  10. Receipt of blood transfusion or blood-derived products within the previous 3 months.
  11. Previous severe local or systemic reactions to vaccination.
  12. History of splenectomy
  13. History of seizure in the last 3 years (participants with a history of seizures who have neither required medications nor had a seizure for 3 years are not excluded)
  14. Known autoimmune disease
  15. Asthma other than mild, well-controlled asthma. Exclude participants who:

    1. Use a bronchodilator (beta 2 agonist) daily, or
    2. In the past year have (any of the following):

    i. Had > 1 exacerbation of symptoms treated with oral steroids ii. Routinely used moderate to high dose inhaled corticosteroids (e.g., more than the equivalent of 250 mcg fluticasone; 400 mcg budesonide; 500 mcg beclomethasone; or 1000 mcg triamcinolone/flunisolide, as a daily dose) or theophylline iii. Needed emergency care, urgent care, hospitalization, or intubation for asthma c. Prophylactic bronchodilator use prior to exercise is not exclusionary

  16. Diabetes mellitus type 1 or type 2, including cases controlled with diet alone. (Not excluded: history of isolated gestational diabetes.)
  17. Thyroidectomy, or thyroid disease requiring medication during the last 12 months
  18. Angioedema within the last 3 years if episodes are considered serious or have required medication within the last 2 years
  19. Uncontrolled Hypertension:

    1. If a person has been diagnosed with hypertension during screening or previously, exclude for hypertension that is not well controlled. Well- controlled hypertension is defined as blood pressure consistently ≤ 140 mm Hg systolic and ≤ 90 mm Hg diastolic, with or without medication, with only isolated, brief instances of higher readings, which must be ≤ 150 mm
    2. If a person has NOT been diagnosed with hypertension during screening or previously, exclude for systolic blood pressure ≥ 150 mm Hg at enrollment or diastolic blood pressure ≥ 90 mm Hg at enrolment
  20. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions)
  21. Malignancy (Not excluded: a participant with a surgical excision and subsequent observation period that in the investigator's estimation has a reasonable assurance of sustained cure or is unlikely to recur during the study period)
  22. Psychiatric condition that compromises safety of the participant or precludes compliance with the protocol, specifically excluding persons with psychoses within the past 3 years, ongoing risk for suicide, or history of suicide attempt or gesture within the past 3 years
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 50 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02937233
Other Study ID Numbers  ICMJE 2016P000268
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD: Undecided
Responsible Party Kathryn Stephenson, Beth Israel Deaconess Medical Center
Study Sponsor  ICMJE Kathryn Stephenson
Collaborators  ICMJE
  • Walter Reed Army Institute of Research (WRAIR)
  • National Institute of Allergy and Infectious Diseases (NIAID)
Investigators  ICMJE Not Provided
PRS Account Beth Israel Deaconess Medical Center
Verification Date August 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP